Australia's Imricor Medical jumps most in 1 month on clinical trial approval
08/03/2024 04:52
** Shares of Imricor Medical Systems IMR.AX rise as much
as 7.6% to A$0.495, their biggest intraday pct gain since Feb 7
** Stock at its highest since March 1
** The medical devices developer says the ethics committee
at Lausanne University Hospital has approved VISABL-AFL clinical
trial
** VISABL-AFL is the global trial to support US FDA approval
of Imricor's products
** Imricor stock down ~17% YTD
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion